Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings
The state of different aminergic receptors was assessed, by quantitative autoradiography in tissue sections, in several representative brain regions from a typical progressive supranuclear palsy (PSP) patient and from 9 matched brains. The densities of muscarinic receptors were within control limits in most of the brain areas of this PSP brain. Serotonin1 receptors were clearly reduced only in areas with very relevant neuropatho-logical damage, such as locus niger and globus pallidus. The density of D1 dopamine receptors in the caudate-putamen and frontal cortex of the patient was within control limits. By contrast, nigral D1 and striatal D2 dopamine receptors were dramatically reduced in the patient as compared to controls. Finally, alpha2-adrenoceptors were clearly reduced in all the examined areas of this PSP patient as compared to control group. Both the potential role of these receptor changes in the pathophysiology of the clinical features of PSP and their correlation with the neuropathological findings of this PSP patient are discussed.
KeywordsDopamine Receptor Progressive Supranuclear Palsy Progressive Supranuclear Palsy Locus Ceruleus Neurofibrillary Degeneration
Unable to display preview. Download preview PDF.
- Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworths, London, pp 166–230.Google Scholar
- Barr AN (1986) Progressive supranuclear palsy. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of clinical neurology, vol 49. Extrapyramidal disorders. Elsevier, Amsterdam, pp 239–254.Google Scholar
- Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Nathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak SJ (1992) Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31: 184–192.PubMedCrossRefGoogle Scholar
- Ghika AJ, Tennis M, Schoenfield D, Growdon JH (1991) Idazoxan improves motor function in progressive supranuclear palsy. Neurology 41[Suppl 1]: 173.Google Scholar
- Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworths, London, pp 124–165.Google Scholar
- Klawans HL, Ringel SP (1978) Observations on the efficacy of L-dopa in progressive supranuclear palsy. J Can Sci Neurol 5: 167–173.Google Scholar
- Steele JC (1975) Progressive supranuclear palsy. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 22. System disorders and atrophies. North-Holland, Amsterdam, pp 217–230.Google Scholar